IXHL
Incannex Healthcare Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$3.24
−0.18%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.7x
Market Cap
$38.82M
MomentumView details →
1D Return
−0.18%
YTD Return
−69.09%
RSI (14)
48.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.7x
Market Cap
$38.82M
RSI (14)
48.1
MomentumView details →
1D Return
−0.18%
YTD Return
−69.09%
SummaryUpdated Mar 1, 2026
Incannex Healthcare Limited (ASX:IXHL) is an Australian pharmaceutical company that develops medicinal cannabinoid products for various medical conditions. Founded in 2001 and originally known as Impression Healthcare Limited, the company rebranded to Incannex Healthcare in June 2020 to reflect its focus on cannabinoid-based therapeutics. The company went public on the Australian Securities Exchange in March 2022. Incannex is currently in the clinical development phase, with multiple drug candidates in various stages of trials targeting conditions such as obstructive sleep apnea, traumatic brain injury, and inflammatory diseases.
Similar companies
Latest newsMore news →
Incannex Healthcare Inc. commenced participant screening in its DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea.43d agoIncannex Healthcare Inc. received a U.S. patent grant from the USPTO for its IHL-42X composition and methods for treating Obstructive Sleep Apnea.71d ago